Harmony Biosciences Holdings, Inc. (HRMY) stock: price, suppliers, customers and institutional ownership
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Harmony Biosciences Holdings, Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Pharmaceutical Preparations
High 43.16 at 1:45 pm ET, low 42.04 at 4:00 pm ET.
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.
the bull case· 2
323
managers reporting a position in regulatory filings
13fJun 30 '26+5.93%
change in shares held by the largest reporting managers over the latest quarter
13fJun 30 '26the bear case· 4
38.00%
share of revenue coming from the largest disclosed customer Caremark LLC
10-Kfiled Feb 24 '260.05%
share of iShares Russell ETF assets representing the largest fund weight on file
n-portJun 30 '2642
managers whose positions together make up the vast majority of reported value
13fJun 30 '267 of 23
of the largest reporting managers that trimmed their stake in the latest quarter
13fJun 30 '26Sides and captions by the model; every figure is ours. Built Sep 16 '26 for the Nov 3 '26 report. Not a forecast, not advice.
Of the 6 companies Harmony Biosciences Holdings, Inc. moves with most closely, none share its SEC classification.
Measured against 149 trading days of our own closes. Co-movement, not cause.
SIC 2834, Pharmaceutical Preparations, from each company's own filings. Largest first.
323 managers report a position worth $2.0B between them, and 42 of them hold 80% of it.
tall tick = annual report · 1 on record
HRMY (Harmony Biosciences Holdings, Inc.) has 13 disclosed suppliers and 3 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for its filing sentence; select again to open the company. Nearer the centre, the more the filings disclose. Extended: satellites hang off single companies, not bundled sectors.